Navigation Links
Protein Shown to Play a Key Role in Normal Development of Nervous System

- Findings May Someday Inform Treatments for Spinal Cord, Other Nerve Injuries -

PHILADELPHIA, Oct. 8 /PRNewswire-USNewswire/ -- A protein that enables nerve cells to communicate with each other plays a key role in controlling the developing nervous system. Research into how that protein helps precise connections to form among nerve cells may provide a basis for eventual treatments for patients who suffer injuries to their nervous system, including spinal cord injury.

"This expands our basic knowledge of how the nervous system develops in animals and humans," said study leader Robert Kalb, M.D., a neurologist at The Children's Hospital of Philadelphia. Kalb and colleagues published two studies in the Journal of Neuroscience.

The first study, published Oct. 1, showed that the protein GluR1, which is a receptor for the neurotransmitter glutamate, promotes the growth of dendrites, both in nerve cell cultures and in the nervous system of mice. Dendrites are branching extensions of nerve cells that carry signals into the cell. The most vigorous dendrite growth occurs shortly after birth, when GluR1 is present on the surface of the cell. As neurons mature, GluR1 is lost from the cell surface of some neurons, and dendrites stop growing.

Kalb and colleagues showed that suppressing GluR1 activity reduced dendrite growth, and led to poor development of connections between neurons. As a result of these defects, mice displayed less strength and less endurance on treadmill tests. On the other hand, using genetic manipulation that led to cell surface expression of GluR1 protein in adult mice led to supernormal motor performance, as shown by longer duration on treadmills.

"Our observations could be relevant to helping patients recover motor function after they suffer an injury to the spinal cord or other parts of the nervous system," said Kalb. "Often neural circuits remain intact after an injury, and are capable of reorganizing themselves, given the proper stimulation. If we can eventually manipulate this protein's activity in neurons, we might enhance communication among those neurons, and allow patients to receiver greater benefit from therapeutic exercises."

The second study by Kalb and colleagues, published Oct. 8, described the molecular pathways by which GluR1 binds with another protein, SAP97, to control dendrite growth during the early postnatal period. "Our work suggests that GluR1 brings the scaffolding protein SAP97 to the membrane of nerve cells, where it can receive pro-growth signals to build dendrites."

Although both studies were performed in mice, the neurodevelopmental process is considered to be similar for all mammals. "The first few weeks of postnatal life are a critical period for sculpting the architecture of the nervous system," added Kalb. "Greater understanding of how neural architecture develops normally may give us insight into how to intervene when things go wrong."

Both studies received grant support from the U.S. Public Health Service, part of the National Institutes of Health. The Pennsylvania Department of Health also provided funding. Dr. Kalb's co-authors included collaborators from the United States (from The Children's Hospital of Philadelphia, Johns Hopkins University and the State University of New York, Buffalo) and abroad, in Germany and Japan.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit

Contact: Rachel Salis-Silverman

Phone: (267) 426-6063

SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. St. Jude Study Gives New Insights Into How Cells Accessorize Their Proteins
2. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
3. Protein Key to Control Growth of Blood Cells
4. Phase II Data on Lillys Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with Alzheimers Disease
5. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
6. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
7. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
8. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
9. Nostrum Announces the Successful Completion of Early Proof-of-Concept Study for its Novel Clot Busting Therapeutic Protein
10. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
11. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... au traitement photodynamique au Bremachlorin contre le cancer ... approche consistant à combiner l,immunothérapie au traitement photodynamique ... --> Une nouvelle approche consistant ... contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... Ein neuer Kombinationsansatz vereint ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... --> Ein neuer Kombinationsansatz vereint Immuntherapie ... Clinical Cancer Research vom 6. November ... vom 6. November 2015 berichtet. --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The rapid speed at ... people age, more care is needed, especially with Alzheimer’s, dementia and other cognitive ... being overworked. The forgotten part of this equation: 80 percent of medical care ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss ... to treat it. Surviving Mesothelioma has just posted the findings on the website. ... Zurich analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed ...
(Date:11/27/2015)... ... 27, 2015 , ... An inventor, from Hopkinsville, Ky., thought ... at home, so he invented the patent-pending ELECTRONIC M.D. , The ELECTRONIC M.D. ... doing so, it could help to prevent potential overdose situations. As a result, ...
(Date:11/27/2015)... ... 2015 , ... "When I was traveling, I was very ... "Many people catch diseases simply from sitting on such dirty toilet seats. I ... germs." , He developed the patent-pending QUDRATECS to eliminate the need to sit ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
Breaking Medicine News(10 mins):